THOUGHT LEADERSHIP

The PROMETRIKA team attended the Fierce Biotech Week conference, which offered a front row seat to the evolving landscape of clinical research, where innovation is not just a buzzword but a driving force. The conversations centered around the growing adoption of Risk-Based Quality Management (RBQM) and the ongoing evolution of the Trial Master File (TMF) as a critical tool for inspection readiness. These topics not only dominated sessions and panels, they sparked dynamic roundtable discussions, signaling a shift in how the industry is approaching trial efficiency, compliance and data integrity.

As the role of statisticians continues to change in a rapidly advancing digital landscape, adaptability and continued learning matter now more than ever. To this end, PROMETRIKA supports its team members in attending conferences where the most current methods and industry guidance are discussed. the annual American Statistical Association (ASA) Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Rockville, MD,features representation from the pharmaceutical industry, academia, and the FDA. The most recent conference focused heavily on the evolving role of statisticians in the artificial intelligence (AI) and machine learning (ML) era. A consensus emerged regarding AI and ML, following innovative perspectives shared by several speakers. While both are viewed as powerful tools with great potential to more efficiently deliver life-saving therapies to patients, caution must be exercised in model implementation.

At PROMETRIKA, we continuously evaluate how emerging technologies can strengthen clinical trial execution, compliance, and data integrity. As trials become more complex and adaptive, systems like Interactive Response Technologies (IRT) - also known as Randomization and Trial Supply Management (RTSM) – need to adapt accordingly to keep up with the increased demands of these trial designs.

The ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop is held annually in Rockville, MD to provide biostatisticians with the opportunity to collaborate and expand the frontiers of statistical knowledge. The 2025 ASA conference centered around the future of statistics in the era of artificial intelligence (AI) and machine learning (ML). Two statisticians attended on behalf of PROMETRIKA to explore current AI/ML research efforts and use cases from statisticians across industry, academia, and regulatory agencies. Across a three-day series of short courses, speaker sessions, panels, roundtables, and poster sessions, a clear message emerged that AI/ML has a strong potential to improve statistical frameworks throughout the drug development life cycle.

The development of ‘artificial intelligence’(AI)-driven tools for data management has accelerated in the past few years. The promise of these systems is to provide a more intuitive experience for data management and sponsor teams, making it easier to track trends, spot anomalies, and generate near-real time data reports. These features, combined with AI’s ability to learn from data, make these tools a modern essential for improving data quality and accelerating clinical trials.